The reported discussions come at a time when Allergan is attempting to shake off a $53 billion acquisition bid from Quebec, Canada-based Valeant Pharmaceuticals, according to the report. Allergan believes the bid from Valeant is “underpriced and too risky,” according to the report.
If Allergan and Salix were to merge, the newly joined market value could make it more difficult for Valeant to successfully acquire Allergan due to the increased value and complexity, according to the report.
More articles on acquisitions:
Hospital M&A activity dips slightly in first half of 2014
Prime Healthcare, Daughters of Charity Health reportedly considering merger
MedAssets to acquire Sg2
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
